Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

125.86 -2.26 (-1.76%)
Streaming Delayed Price Updated: 3:17 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
69 70 Next >
Seagen Stock Soars On Pfizer Takeover Talks: What's Going On?
Seagen Inc (NASDAQ: SGEN) shares are trading higher Monday following reports indicating pharmaceutical giant Pfizer Inc (NYSE: 
Via Benzinga
Pfizer In Early Talks To Buy Cancer-Focused Seagen: WSJ
Via Benzinga
Buy/Sell: Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 25
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street’s best analysts during the week of Feb. 20-24. 
Via Talk Markets
US Senators Warren, Sanders Urge 'Close Scrutiny' On Merck's Keytruda-Related Patents
Via Benzinga
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
European Authority Recommends Against Approval For Merck-Ridgeback Biotherapeutics' COVID-19 Pill
Via Benzinga
Expert Ratings for Merck & Co
Via Benzinga
Merck's COVID-19 Treatment Fails To Prevent Infection In Household Exposure
Via Benzinga
Why Shares of Organon Fell 15% Thursday
The company reported fourth-quarter and year-end financials. 
Via The Motley Fool
Don't Get Panicked Into Selling Off Merck Shares
The current drop in 2023 sales likely won't matter in the long term. 
Via The Motley Fool
Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge
Via Benzinga
Moderna Pops After FDA Grants Its Cancer Vaccine A Breakthrough Designation
The companies could see a speedier review process. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
Via Benzinga
2 Ultra-Safe Dividend Stocks to Buy Right Now
These two dividend stocks are top buys for investors concerned about an economic slowdown. 
Via The Motley Fool
This Recession-Proof Company Has a Best-in-Class Dividend
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
Jim Cramer Lists 6 Conditions For Market Selloff To End Amid 'Discouraging' Inflation Data
Prominent market commentator Jim Cramer on Tuesday suggested a six-point checklist of events that must happen before declaring an end to the market sell-off. 
Via Benzinga
3 Large-Cap Biotech Stocks to Hold for the Long Haul
These three large-cap biotech stocks survived or went up in 2022 when most of the market went down by double digits. 
Via InvestorPlace
2022 Annual Review
In this annual review, I look at my dividend portfolio's performance as measured by dividend income, dividend increases, annualized returns, and rate of return. I also share some highlights of the past... 
Via Talk Markets
I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said.
We asked ChatGPT to name various types of stocks to buy. Can the latest artificial intelligence craze get things right? 
Via InvestorPlace
Should Income Investors Buy This Dow Jones Stock?
This drugmaker boasts an impressive product portfolio and pipeline. 
Via The Motley Fool
Merck Says Keytruda/Chemo Combo Improved Overall Survival Compared To Chemo Alone In Gastric Cancer Settings
Via Benzinga
2 Market-Beating Dividend Stocks to Buy With $500
These two leading healthcare stocks have been rewarding shareholders with dividends for a while. 
Via The Motley Fool
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among... 
Via Benzinga
Robinhood, Merck And 2 Other Stocks Insiders Are Selling
The Nasdaq closed higher by around 0.6% on Tuesday, also recording losses for the week. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Amesite Inc. (NASDAQ: AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users. 
Via Benzinga
BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype
Via Benzinga
Acurx is Setting a High Bar for New Treatments in C. diff
A New Gold Standard for C. diff Therapy Could be in the Offing;  Next Data Release Expected in 2Q23 
Via Benzinga
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
New 52-Week Highs In 2023
20% of stocks in the large-cap Russell 1,000 have made 52-week highs at some point so far in 2023. 
Via Talk Markets
Stellar Opportunity For Merck At Upcoming Data Presentation, Analyst Says While Boosting Price Target
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
69 70 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.